The IL-23/IL-17 axis is known to be highly expressed in psoriatic skin lesions via the JAK/STAT signaling pathway, and JAK inhibitors have been used to treat psoriasis lesions [23,24]. This evidence concerns the gene IL17A and psoriasis.